person · Reporting owner

Thompson Tommy G

Disclosed activity across 8 companies

Tapewire entity: 29039
SEC CIK: 0001324863

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BARD C R INC /NJ/BCR · Entity 170698	Director	December 29, 2017	January 03, 2018
CENTENE CORPCNC · Entity 3133	Director	December 31, 2021	January 05, 2022
HEALTHPEAK PROPERTIES, INC.DOC · Entity 3364	Director	May 28, 2025	May 28, 2025
Scilex Holding CoSCLX · Entity 7345	Director	January 17, 2023	January 17, 2023
TYME TECHNOLOGIES, INC.TYME · Entity 123718	Director	August 22, 2019	August 27, 2019
TherapeuticsMD, Inc.TXMD · Entity 7541	Director	December 23, 2025	December 29, 2025
UNITED THERAPEUTICS CorpUTHR · Entity 664	Director	July 22, 2026	July 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BARD C R INC /NJ/

Report date December 29, 2017 · Filed January 03, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-12-29 transaction · row 1 1 source row Row 1 · 2017-12-29 · Disposition to issuer · Disposed 6,293 · Balance 0 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration").
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.76 · Expires 2018-07-09	Direct	0	Reported balance After 2017-12-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-12-29 · Disposition to issuer · Disposed 1,200 · Balance 0 F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated. F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.70 · Expires 2019-12-09	Direct	0	Reported balance After 2017-12-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-12-29 · Disposition to issuer · Disposed 1,200 · Balance 0 F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated. F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Phantom Stock UnitsSEC Table II · derivative / convertible security	Direct	8,028.46	Reported balance After 2017-12-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-12-29 · Grant · Acquired 37.65 · Balance 8,028.46 F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees. F5: Conversion is 1 for 1. F6: Phantom stock units are settled in cash upon termination of service as director. F7: Includes 50.46 units for dividend credits.
Phantom Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-12-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-12-29 · Disposition to issuer · Disposed 8,028.46 · Balance 0 F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees. F5: Conversion is 1 for 1. F8: These units, which are 100% vested, were paid out in cash in accordance with the Merger Agreement.
Share Equivalent UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-12-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-12-29 · Disposition to issuer · Disposed 8,541 · Balance 0 F9: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F10: These units, which are 100% vested, were assumed by BD at the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration").

F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated.

F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees.

F5: Conversion is 1 for 1.

F6: Phantom stock units are settled in cash upon termination of service as director.

F7: Includes 50.46 units for dividend credits.

F8: These units, which are 100% vested, were paid out in cash in accordance with the Merger Agreement.

F9: Units granted under the Company's Stock Equivalent Plan for Outside Directors.

F10: These units, which are 100% vested, were assumed by BD at the effective time of the Merger.

CENTENE CORP

Report date December 31, 2021 · Filed January 05, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	227,334.239	Reported balance After 2021-12-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-12-31 · Grant · Acquired 450.241 · Balance 227,334.239 F1: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	26,896	Reported balance Holding disclosure · report date 2021-12-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 26,896 F2: Shares held by a family investment LLC.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	74,000	Reported balance Holding disclosure · report date 2021-12-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 74,000 F3: Shares held by the Sue Ann Thompson Endowment Trust.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	60,000	Reported balance Holding disclosure · report date 2021-12-31 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 60,000 F4: Shares held by the Tommy G Thompson Family Endowment Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.

F2: Shares held by a family investment LLC.

F3: Shares held by the Sue Ann Thompson Endowment Trust.

F4: Shares held by the Tommy G Thompson Family Endowment Trust.

HEALTHPEAK PROPERTIES, INC.

Report date May 28, 2025 · Filed May 28, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	144,290	Reported balance After 2025-05-28 transaction · row 1 1 source row Row 1 · 2025-05-28 · Purchase · Acquired 5,777 · Balance 144,290

Scilex Holding Co

Report date January 17, 2023 · Filed January 17, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2033-01-17	Direct	250,000	Reported balance After 2023-01-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-17 · Grant · Acquired 250,000 · Balance 250,000 F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

TYME TECHNOLOGIES, INC.

Report date August 22, 2019 · Filed August 27, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option - right to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2029-08-21	Direct	50,000	Reported balance After 2019-08-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-08-22 · Grant · Acquired 50,000 · Balance 50,000 F1: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments.

Filing footnotes · ownership attribution and instrument terms

F1: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments.

TherapeuticsMD, Inc.

Report date December 23, 2025 · Filed December 29, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,179	Reported balance After 2025-12-23 transaction · row 1 1 source row Row 1 · 2025-12-23 · Purchase · Acquired 8,400 · Balance 23,179
Common StockSEC Table I · non-derivative	IndirectThompson Family Holdings, LLC, owned by Mr. Thompson.	21	Reported balance Holding disclosure · report date 2025-12-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 21
Common StockSEC Table I · non-derivative	IndirectThompson Family Investments, LLC, owned by Thompson Family Holdings, LLC, owned by Mr. Thompson	14,312	Reported balance Holding disclosure · report date 2025-12-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 14,312

UNITED THERAPEUTICS Corp

Report date July 22, 2026 · Filed July 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	380	Reported balance After 2026-07-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-07-22 · Grant · Acquired 380 · Balance 380 F2: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3: Annual non-employee director award. F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F5: Not applicable as restricted stock units do not have an expiration date.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22	Direct	1,190	Reported balance After 2026-07-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-07-22 · Grant · Acquired 1,190 · Balance 1,190 F3: Annual non-employee director award. F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Common StockSEC Table I · non-derivative	Direct	8,480	Reported balance Holding disclosure · report date 2026-07-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 8,480 F1: Includes 880 shares of common stock issued on July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares.
Common StockSEC Table I · non-derivative	Indirectby Trust	8,200	Reported balance Holding disclosure · report date 2026-07-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 8,200
Common StockSEC Table I · non-derivative	Indirectby Family LLC	5,800	Reported balance Holding disclosure · report date 2026-07-22 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,800

Filing footnotes · ownership attribution and instrument terms

F1: Includes 880 shares of common stock issued on July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares.

F2: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3: Annual non-employee director award.

F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

F5: Not applicable as restricted stock units do not have an expiration date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Physicians Realty Trust

Report date March 01, 2024 · Filed March 01, 2024

Section 16 reporting ended · disclosed 2024-03-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common shares, $0.01 par valueSEC Table I · non-derivative	Direct	Ending reported balance After 2024-03-01 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-03-01 · Exercise / conversion · Acquired 4,582 · Balance 156,830 F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024. Row 2 · 2024-03-01 · Exercise / conversion · Acquired 10,205 · Balance 167,035 F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024. Row 3 · 2024-03-01 · Disposition to issuer · Disposed 167,035 · Balance 0 F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest.
Common shares, $0.01 par valueSEC Table I · non-derivative	IndirectRepresents shares held by Thompson Family Charitable Foundation	Reported balance After 2024-03-01 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2024-03-01 · Disposition to issuer · Disposed 25,635 · Balance 0 F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest.
2022 Restricted Share Unit GrantSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-03-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-03-01 · Exercise / conversion · Disposed 4,582 · Balance 0 F3: On March 1, 2022, the Reporting Person was granted 9,164 restricted stock units, which vest in two equal installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.
2023 Restricted Share Unit GrantSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-03-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-03-01 · Exercise / conversion · Disposed 10,205 · Balance 0 F4: On March 1, 2023, the Reporting Person was granted 10,205 restricted stock units, which vest in two equal installments on March 1, 2024 and March 1, 2025, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024.

F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest.

F3: On March 1, 2022, the Reporting Person was granted 9,164 restricted stock units, which vest in two equal installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.

F4: On March 1, 2023, the Reporting Person was granted 10,205 restricted stock units, which vest in two equal installments on March 1, 2024 and March 1, 2025, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 22, 2017 Filed Mar 23, 2017 20:26 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	2,000	$54.77	$109,540.00	Disclosure SEC source: 0001127602-17-012824 · form4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of a cash-settled share tracking award. Read SEC document
March 03, 2017 Filed Mar 7, 2017 22:30 UTC	Physicians Realty Trust DOC · Entity 93614	GrantCommon Shares, $0.01 par value	7,576	$0.00	$0.00	Disclosure SEC source: 0001209191-17-018889 · doc4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,210 F1 · security: March 3, 2017 grant of time based restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 3, 2018 and March 3, 2019, subject to the terms of the grant. Each time based restricted stock unit represents a contingent right to receive one share of the Issuer's common shares. Read SEC document
January 03, 2017 Filed Jan 5, 2017 14:11 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantPhantom Stock Units · Derivative	104.96	$227.47	$23,875.25	Disclosure SEC source: 0001225208-17-000581 · doc4.xml · derivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,891.19 Underlying: Common Stock · 104.96 shares Expires not disclosed F1 · security: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees. F2 · derivative.exercise_price: Conversion is 1 for 1. F3 · derivative.exercise_date: Phantom stock units are settled in cash upon termination of service as director. F3 · derivative.expiration_date: Phantom stock units are settled in cash upon termination of service as director. F4 · balance_after: Includes 18.32 units for dividend credits. Read SEC document
December 31, 2016 Filed Jan 5, 2017 01:32 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	593.12	$59.01	$35,000.01	Disclosure SEC source: 0001071739-17-000007 · wf-form4_148357993412878.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,899.511 F1 · balance_after: Ownership includes 3,350 shares of restricted stock subject to vesting requirements. Read SEC document
December 21, 2016 Filed Dec 23, 2016 00:10 UTC	TherapeuticsMD, Inc. TXMD · Entity 7541	GrantNon-Qualified Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $5.68	$0.00	Disclosure SEC source: 0001387131-16-008708 · thompson-form4_12212016.xml · derivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 Read SEC document
December 14, 2016 Filed Dec 15, 2016 15:58 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantShare Equivalent Units · Derivative	375	$0.00	$0.00	Disclosure SEC source: 0001225208-16-043308 · doc4.xml · derivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,296 Underlying: Common Stock · 375 shares Expires not disclosed F2 · security: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F3 · derivative.exercise_price: Conversion is 1 for 1. F4 · derivative.exercise_date: Share Equivalent Units are settled in cash upon termination as a director. F4 · derivative.expiration_date: Share Equivalent Units are settled in cash upon termination as a director. Read SEC document
December 14, 2016 Filed Dec 15, 2016 15:58 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantCommon Stock	468	$0.00	$0.00	Disclosure SEC source: 0001225208-16-043308 · doc4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,004 F1 · kind: Stock award granted in accordance with the 2005 Directors' Stock Award Plan, as amended and restated, that fully vests in three years from the date of grant. Read SEC document
November 23, 2016 Filed Nov 28, 2016 16:07 UTC	Physicians Realty Trust DOC · Entity 93614	PurchaseCommon shares, $0.01 par value	2,100	$18.05	$37,905.00	Disclosure SEC source: 0001209191-16-152083 · doc4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,938 Read SEC document
November 17, 2016 Filed Nov 21, 2016 20:49 UTC	Physicians Realty Trust DOC · Entity 93614	PurchaseCommon shares, $0.01 par value	14,400	$18.04	$259,776.00	Disclosure SEC source: 0001209191-16-151414 · doc4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Thompson Family Investments, LLC Disclosed balance after: 24,849 F1 · price: The price reported in Column 4 is a weighted average price. These common shares were purchased in multiple transactions at prices ranging from $17.84 to $18.15, inclusive. The reporting person undertakes to provide to Physicians Realty Trust, any security holder of Physicians Realty Trust, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of common shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
September 30, 2016 Filed Oct 4, 2016 23:32 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	503.815	$69.47	$35,000.03	Disclosure SEC source: 0001071739-16-000283 · wf-form4_147562395693523.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,306.391 F1 · balance_after: Ownership includes 3,350 shares of restricted stock subject to vesting requirements. Read SEC document
September 26, 2016 Filed Sep 27, 2016 21:01 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionShare Tracking Award · Derivative	1,291	$0.00 Strike: $48.11	$0.00	Disclosure SEC source: 0001127602-16-063280 · form4.xml · derivative · entry 3 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,709 Underlying: Common Stock · 1,291 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of a cash-settled share tracking award. Read SEC document
September 26, 2016 Filed Sep 27, 2016 21:01 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	1,291	$125.57	$162,110.87	Disclosure SEC source: 0001127602-16-063280 · form4.xml · nonDerivative · entry 2 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Exercise of a cash-settled share tracking award. Read SEC document
September 26, 2016 Filed Sep 27, 2016 21:01 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	1,291	$48.11	$62,110.01	Disclosure SEC source: 0001127602-16-063280 · form4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of a cash-settled share tracking award. Read SEC document
June 21, 2016 Filed Mar 7, 2017 22:02 UTC Amendment	UNITED THERAPEUTICS Corp UTHR · Entity 664	GrantStock Options · Derivative	4,910	$0.00 Strike: $101.80	$0.00	Disclosure SEC source: 0001127602-17-010640 · form4a.xml · derivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2026-06-21 F1 · shares: The purpose of this amendment is to correct an overstatement of the number of shares subject to the stock option awarded to the reporting person on June 21, 2016, by 90 shares. The original Form 4 filing on June 23, 2016 reported 5,000 shares subject to this stock option. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.